Compare HELP & EOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HELP | EOD |
|---|---|---|
| Founded | N/A | 2007 |
| Country | Canada | United States |
| Employees | 50 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 279.9M | 271.7M |
| IPO Year | N/A | N/A |
| Metric | HELP | EOD |
|---|---|---|
| Price | $5.06 | $6.53 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $51.50 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 111.4K |
| Earning Date | 07-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.28% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.29 | $5.14 |
| 52 Week High | $8.55 | $6.51 |
| Indicator | HELP | EOD |
|---|---|---|
| Relative Strength Index (RSI) | 45.14 | 66.80 |
| Support Level | $4.63 | $5.56 |
| Resistance Level | $6.26 | N/A |
| Average True Range (ATR) | 0.45 | 0.11 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 14.09 | 89.53 |
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.